Jyong Biotech (MENS) Registration Filing summary

Company overview and business model

• Science-driven biotech firm based in Taiwan, focused on developing and commercializing plant-derived drugs for urinary system diseases, targeting the U.S., EU, and Asia markets.

• Operates through five wholly owned subsidiaries in Taiwan, Singapore, Hong Kong, and China; holding company structure in the Cayman Islands.

• Core pipeline includes MCS-2 for benign prostate hyperplasia/lower urinary tract symptoms (BPH/LUTS), PCP for prostate cancer prevention, and IC for interstitial cystitis.

• Integrated in-house capabilities span drug discovery, clinical trials, regulatory affairs, manufacturing, and commercialization.

• No commercialized products or revenue to date; business model relies on R&D, regulatory approval, and future commercialization or licensing.

Financial performance and metrics

• No revenue generated as of June 30, 2024; accumulated deficit of $31.4 million.

• Net losses: $6.6 million (2022), $4.4 million (2023), $1.3 million (six months ended June 30, 2024).

• Net working capital deficit: $12.5 million (Dec 31, 2023), $11.7 million (June 30, 2024).

• Cash and equivalents: $96,000 as of June 30, 2024.

• Research and development expenses: $1.3 million (2022), $1.1 million (2023), $0.5 million (six months ended June 30, 2024).

• Auditor and management have raised substantial doubt about ability to continue as a going concern.

Use of proceeds and capital allocation

• IPO proceeds primarily allocated to: 30% ($8.7M) for Phase III trials of MCS-2 (API-2) and NDA, 10% ($2.9M) for PCP Phase II, 5% ($1.45M) for IC Phase I, 15% ($4.35M) for manufacturing bases, 15% ($4.35M) for business development, 10% ($2.9M) for litigation settlement and commitments, 15% ($4.35M) for general corporate purposes.

• Proceeds will not be sufficient to fund all drug candidates through regulatory approval; additional $10M in capital will be needed.